Skip to content
Acceleron Pharma

Investors/Media

Press Releases

Filter Releases
 
Press Releases
Date Title and Summary View
Nov 15, 2017
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN) today announced the appointment of the experienced biopharmaceutical executive, Karen Smith, M.D., Ph.D., to its board of directors and the departure of Terrance McGuire, effective November 15, 2017. "Karen's breadth ...
Nov 14, 2017
- Preclinical results show potential first-in-class disease-modifying properties of sotatercept in pulmonary arterial hypertension - - Company expects to initiate a Phase 2 trial in 1H 2018 - CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a leading b...
Nov 7, 2017
-Presented vision and strategic focus in hematological, neuromuscular, and pulmonary diseases at September R&D Day- -Obtained the rights to fund, develop, and lead global commercialization of sotatercept in pulmonary arterial hypertension; robust preclinical results show potential for first-in-cla...
Nov 1, 2017
- Presentations to highlight efficacy, duration of response, and long-term safety results from ongoing Phase 2 studies in myelodysplastic syndromes and myelofibrosis - CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the...
Oct 26, 2017
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN) today announced it will host a webcast and conference call on Tuesday, November 7, 2017 at 8:00 a.m. EST to discuss its third quarter 2017 financial results and provide an update on recent clinical development and corporate activities. ...
Oct 5, 2017
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ: XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that it has issued 810,810 shares of common stock at the public offering price of $37.00 ...
Sep 20, 2017
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics intended to treat serious and rare hematologic, neuromuscular, and pulmonary diseases, today announced that it has priced an underwritten public ...
Sep 19, 2017
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ: XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare hematologic, neuromuscular, and pulmonary diseases, today announced that it intends to offer and sell, subject to ...
Sep 19, 2017
- Clinical development and research efforts focused on hematological, neuromuscular and pulmonary diseases - CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat ...
Sep 19, 2017
- Acceleron gains rights to fund, develop, and lead global commercialization of sotatercept in pulmonary arterial hypertension - - Acceleron expects to initiate a Phase 2 trial of sotatercept in pulmonary arterial hypertension in 1H 2018 - - Preclinical results show potential first...
Sep 12, 2017
- Acceleron's senior management team and external experts to present clinical development programs and preclinical research efforts - - Live conference call and webcast scheduled for 8:00 a.m. EDT on September 19th - CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Phar...
Sep 5, 2017
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ: XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, announced that The Lancet Oncology has published results from the Phase 2 ...
Aug 3, 2017
- Completed full enrollment of luspatercept MEDALIST and BELIEVE Phase 3 trials - - Presented updated luspatercept Phase 2 results in patients with MDS and beta-thalassemia receiving treatment for up to two years - - Treated first patient in ACE-083 Phase 2 study in Charco...
Aug 1, 2017
- Phase 2 trial in CMT expands wholly-owned ACE-083 program and muscle franchise into new area of high unmet medical need - CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercial...
Jul 27, 2017
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN) today announced it will host a webcast and conference call on Thursday, August 3, 2017 at 5:00 p.m. EDT to discuss its second quarter 2017 financial results and provide an update on recent clinical development and corporate activities. ...
Page:
...
Next Last
 
= add release to Briefcase